These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 28383790

  • 1. Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study.
    Leyssens A, Dierickx D, Verbeken EK, Tousseyn T, Verleden SE, Vanaudenaerde BM, Dupont LJ, Yserbyt J, Verleden GM, Van Raemdonck DE, Vos R.
    Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28383790
    [Abstract] [Full Text] [Related]

  • 2. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM, Alhomayeed B, Soliman N, Weir MA, House AA.
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [Abstract] [Full Text] [Related]

  • 3. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM, Burkett P, Divo M, Keller S, Rosas IO, Trindade A, Mody GN, Singh SK, El-Chemaly S, Camp PC, Goldberg HJ, Mallidi HR.
    Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
    [Abstract] [Full Text] [Related]

  • 4. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E, Guzzo I, Morolli F, Longo G, Russo C, Lombardi A, Merli P, Barzon L, Murer L, Piga S, Ciofi Degli Atti ML, Locatelli F, Dello Strologo L.
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [Abstract] [Full Text] [Related]

  • 5. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, Handy J.
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [Abstract] [Full Text] [Related]

  • 6. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
    Smith JM, Corey L, Healey PJ, Davis CL, McDonald RA.
    Transplantation; 2007 Jun 15; 83(11):1423-8. PubMed ID: 17565314
    [Abstract] [Full Text] [Related]

  • 7. Clinical and virologic outcomes in high-risk adult Epstein-Barr virus mismatched organ transplant recipients.
    Kumar D, Patil N, Husain S, Chaparro C, Bhat M, Kim SJ, Humar A.
    Clin Transplant; 2017 Jul 15; 31(7):. PubMed ID: 28489256
    [Abstract] [Full Text] [Related]

  • 8. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients.
    Baldanti F, Rognoni V, Cascina A, Oggionni T, Tinelli C, Meloni F.
    Virol J; 2011 Sep 05; 8():421. PubMed ID: 21892950
    [Abstract] [Full Text] [Related]

  • 9. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 05; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 10. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
    Fellner MD, Durand KA, Solernou V, Bosaleh A, Balbarrey Z, García de Dávila MT, Rodríguez M, Irazu L, Alonio LV, Picconi MA.
    Rev Argent Microbiol; 2016 Jan 05; 48(2):110-8. PubMed ID: 27157146
    [Abstract] [Full Text] [Related]

  • 11. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E, Cooperative Study Group on PTLDs.
    Haematologica; 2002 Jan 05; 87(1):67-77. PubMed ID: 11801467
    [Abstract] [Full Text] [Related]

  • 12. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
    Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, Khan F, Taparia M, Jimenez-Zepeda VH, Stewart DA, Daly A, Storek J.
    Clin Transplant; 2018 Jan 05; 32(1):. PubMed ID: 29114932
    [Abstract] [Full Text] [Related]

  • 13. Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis.
    Saueressig MG, Boussaud V, Amrein C, Guillemain R, Souilamas J, Souilamas R.
    Clin Transplant; 2011 Jan 05; 25(4):E430-6. PubMed ID: 21518001
    [Abstract] [Full Text] [Related]

  • 14. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA, Verschuuren EA, Erasmus ME, Hepkema BG, Veeger NJ, Kallenberg CG, van der Bij W.
    Transplantation; 2007 Feb 27; 83(4):433-8. PubMed ID: 17318076
    [Abstract] [Full Text] [Related]

  • 15. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.
    Transpl Infect Dis; 2016 Feb 27; 18(1):44-54. PubMed ID: 26574232
    [Abstract] [Full Text] [Related]

  • 16. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Nephrol Dial Transplant; 2012 Jul 27; 27(7):2971-9. PubMed ID: 22273720
    [Abstract] [Full Text] [Related]

  • 17. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease.
    Wong JY, Tait B, Levvey B, Griffiths A, Esmore DS, Snell GI, Williams TJ, Kotsimbos TC.
    Transplantation; 2004 Jul 27; 78(2):205-10. PubMed ID: 15280679
    [Abstract] [Full Text] [Related]

  • 18. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study.
    Allen UD, Farkas G, Hébert D, Weitzman S, Stephens D, Petric M, Tellier R, Ngan B, Fecteau A, West L, Wasfy S.
    Pediatr Transplant; 2005 Aug 27; 9(4):450-5. PubMed ID: 16048596
    [Abstract] [Full Text] [Related]

  • 19. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ, Perrine SP, Faller DV.
    Transpl Infect Dis; 2001 Sep 27; 3(3):177-85. PubMed ID: 11493400
    [Abstract] [Full Text] [Related]

  • 20. Acute cellular rejection and Epstein-Barr virus-related post-transplant lymphoproliferative disorder in a pediatric lung transplant with low viral load.
    Calabrese F, Loy M, Lunardi F, Marino D, Aversa SM, Rea F.
    Transpl Infect Dis; 2010 Aug 01; 12(4):342-6. PubMed ID: 20030794
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.